Cytokine killer cells for grade 4 brain tumor after temozolomide
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a type of immune cell treatment (called cytokine-induced killer cells) for advanced, grade 4 malignant glioma that has come back after prior therapy. It aims to slow or control the tumor by using your immune system after temozolomide treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed grade 4 malignant glioma (a fast-growing brain cancer).
- Your cancer must have returned on MRI after prior treatment, and you should have no more than 3 prior relapses.
- You must have already completed at least one full cycle of temozolomide (a chemotherapy) and not had unacceptable side effects or worsening during it.
- You must be 18 or older, and have enough strength to function (Karnofsky score 60 or higher).
- You must have measurable tumor areas on imaging, and be able to provide stored tumor tissue for review soon after enrollment.
- You must be able to use effective birth control during the study and consent to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a type of immune-cell therapy (cytokine-induced killer cells) for people with certain grade 1–2 aggressive brain tumors that have already been treated with radiation and temozolomide. It aims to see whether the treatment can control the tumor and be tolerated safely.
This trial tests a new approach using immune cells called cytokine-induced killer cells to treat glioblastoma. It aims to find the best way to prepare these cells to fight the tumor.
This early-phase study tests an immune cell treatment (natural killer cells) plus temozolomide to treat melanoma that has spread to the brain. It’s for people whose brain spots are getting worse and who are not good candidates for certain types of brain radiation.
This trial tests a new treatment using donated natural killer (NK) cells injected into the body to fight high-grade brain tumors. It might help people with certain types of aggressive gliomas that are newly diagnosed.
This Phase 1 trial tests a gene-edited immune cell treatment given into the brain to treat recurrent (returning) grade 4 glioblastoma or related tumors. It aims to find a safe dose and see whether the treatment can slow tumor growth.
This early-phase study tests whether liposomal curcumin, added to standard radiation plus temozolomide, can improve treatment outcomes in newly diagnosed high-grade gliomas. It focuses on safety and how well the treatment can be given with the usual therapy plan.
Hear when a new Cytokine-Induced Killer Cells trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.